Antonella Sistigu

Università Cattolica del Sacro Cuore — Italy

Immunology and Microbiology · Life Sciences

34h-index14.3kcitations93works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(39), Cytokine Signaling Pathways and Interactions(25), Cancer Immunotherapy and Biomarkers(17), Immune Cell Function and Interaction(12), Immune cells in cancer(12)

Publications90 total

E. Coli cytotoxic necrotizing factor-1 promotes colorectal carcinogenesis by causing oxidative stress, DNA damage and intestinal permeability alteration
Journal of Experimental & Clinical Cancer Research·2025· 10 citedOpen Access
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Nature Immunology·2024Open Access
Epigenetics behind tumor immunology: a mini review
2024
In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry
Methods in molecular biology·2023
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
Journal of Translational Medicine·2023· 12 citedOpen Access
Epigenetics behind tumor immunology: a mini review
Oncogene·2023· 6 cited
3D cancer models: One step closer to in vitro human studies
Frontiers in Immunology·2023· 74 citedOpen Access
Supplementary Figure 2 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Data from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Figure 2 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Figure 1 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Table 1 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Figure 1 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Table 1 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary figures legend from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Figure 3 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary figures legend from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Data from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Figure 3 from Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
2023Open Access
Supplementary Table 1 from Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Ilio Vitale(21), Gwenola Manic(17), Martina Musella(16), Guido Kroemer(12), Laurence Zitvogel(12), Laura Bracci(11), Giovanna Schiavoni(11), Fabrizio Mattei(9), Claudia Galassi(9), Oliver Kepp(8), Enrico Proietti(8), Ruggero De Maria(8), Lorenzo Galluzzi(7), Filippo Belardelli(7), Sandy Adjemian(6), Lucia Gabriele(6), Paola Sestili(6), Valeria Lucarini(6), Massimo Sanchez(6), Massimo Spada(6)